Journal
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
Volume 128, Issue 2, Pages 507-513Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13813455.2019.1697889
Keywords
Urinary glycosaminoglycans; chondroitin sulphate; dermatan sulphate; heparan sulphate; type 2 diabetes mellitus; metformin; HOMA-IR2
Funding
- Medical University of Silesia in Katowice, Poland [KNW-1-031/N/9/0]
Ask authors/readers for more resources
This study analyzed the pattern of urinary excretion of total sulphated glycosaminoglycans (GAGs) and their particular types in obese patients with type 2 diabetes mellitus (T2DM) treated with metformin. The results showed that metformin therapy for six months significantly decreased the urinary excretion of total GAGs, CS/DS, and HS.
Objective: The pattern of urinary excretion of total sulphated glycosaminoglycans (GAGs) and their particular types: chondroitin sulphate/dermatan sulphate (CS/DS) and heparan sulphate (HS) was analysed in obese patients with type 2 diabetes mellitus (T2DM) treated with metformin in monotherapy for the period of six months. Methods: The urinary sulphated glycosaminoglycans were quantitated using standardised dye (1.9-dimethylmethylene blue)-binding method and normalised to creatinine level. Results: Urinary total GAGs, CS/DS and HS levels were significantly higher in untreated diabetic patients in comparison to healthy subjects. Moreover, it was observed that urinary total GAGs, CS/DS and HS levels in diabetic patients after six-month metformin therapy were significantly decreased versus pre-treatment situation. Conclusions: The obtained results suggest that the six-month treatment with metformin in obese patients with T2DM has a regulating influence on the systemic changes in proteoglycans/glycosaminoglycans, resulting in a decrease in the urinary excretion of total GAGs, CS/DS and HS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available